Teva Pharma (TEVA) Intends to Issue $4B Offering of Sustainability-linked Senior Notes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Teva Pharma (TEVA) Misses Q3 EPS by 6c
October 27, 2021 7:04 AM EDTTeva Pharma (NYSE: TEVA) reported Q3 EPS of $0.59, $0.06 worse than the analyst estimate of $0.65. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $4.03 billion.
GUIDANCE:
Teva Pharma reaffirms FY2021 EPS of $2.50-$2.70 and revenue of... More
Teva Pharma (TEVA) and MODAG Collaborate on Neurodegenerative Disease Drug Candidate
October 26, 2021 4:45 PM EDTTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG's lead compound anle138b and a related compound, sery433.
Anle138b targets pathological alpha-synuclein oligomers and is being evaluated in patients with neurodegenerative diseases for potential disease... More
